Safety and efficacy of dual antiplatelet pretreatment in patients with ischemic stroke treated with IV thrombolysis: A systematic review and meta-analysis.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
18 02 2020
Historique:
received: 19 04 2019
accepted: 29 08 2019
pubmed: 22 1 2020
medline: 6 5 2020
entrez: 22 1 2020
Statut: ppublish

Résumé

Conflicting data exist on the safety and efficacy of IV thrombolysis (IVT) in patients with acute ischemic stroke (AIS) receiving dual antiplatelet pretreatment (DAPP). The aim of the present systematic review and meta-analysis is to assess the safety and outcome of DAPP history among patients with AIS treated with IVT. We performed a comprehensive literature review to identify studies that investigated the safety and efficacy of DAPP among patients with AIS treated with IVT. We identified 9 studies comprising 66,675 patients. In unadjusted analyses, DAPP was associated with a higher likelihood of pooled symptomatic intracranial hemorrhage (sICH; odds ratio [OR] 2.26; 95% confidence interval [CI] 1.39-3.67) and 3-month mortality (OR 1.47; 95% CI 1.25-1.73). DAPP was also related to higher odds of sICH according to Safe Implementation of Treatments in Stroke Monitoring Study (OR 2.71; 95% CI 2.05-3.59), European Cooperative Acute Stroke After adjustment for potential confounders, DAPP appears not to be associated with higher risk of adverse outcomes in patients with AIS treated with IVT.

Identifiants

pubmed: 31959709
pii: WNL.0000000000008961
doi: 10.1212/WNL.0000000000008961
doi:

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

e657-e666

Commentaires et corrections

Type : CommentIn
Type : CommentOn
Type : CommentIn
Type : CommentIn

Informations de copyright

© 2020 American Academy of Neurology.

Auteurs

Konark Malhotra (K)

From the Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, PA; Department of Neurology (A.H.K.), University of Ioannina School of Medicine, Greece; Department of Neurology (N.G., A.W.A., A.V.A, G.T.), University of Tennessee Health Science Center, Memphis; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (D.S.), Helsinki University Central Hospital, Finland; Second Department of Neurology (A.H.K., L.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; and Clinical Innovation and Research Institute (J.C.G.), Memorial Hermann Hospital-Texas Medical Center, Houston.

Aristeidis H Katsanos (AH)

From the Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, PA; Department of Neurology (A.H.K.), University of Ioannina School of Medicine, Greece; Department of Neurology (N.G., A.W.A., A.V.A, G.T.), University of Tennessee Health Science Center, Memphis; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (D.S.), Helsinki University Central Hospital, Finland; Second Department of Neurology (A.H.K., L.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; and Clinical Innovation and Research Institute (J.C.G.), Memorial Hermann Hospital-Texas Medical Center, Houston.

Nitin Goyal (N)

From the Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, PA; Department of Neurology (A.H.K.), University of Ioannina School of Medicine, Greece; Department of Neurology (N.G., A.W.A., A.V.A, G.T.), University of Tennessee Health Science Center, Memphis; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (D.S.), Helsinki University Central Hospital, Finland; Second Department of Neurology (A.H.K., L.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; and Clinical Innovation and Research Institute (J.C.G.), Memorial Hermann Hospital-Texas Medical Center, Houston.

Niaz Ahmed (N)

From the Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, PA; Department of Neurology (A.H.K.), University of Ioannina School of Medicine, Greece; Department of Neurology (N.G., A.W.A., A.V.A, G.T.), University of Tennessee Health Science Center, Memphis; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (D.S.), Helsinki University Central Hospital, Finland; Second Department of Neurology (A.H.K., L.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; and Clinical Innovation and Research Institute (J.C.G.), Memorial Hermann Hospital-Texas Medical Center, Houston.

Daniel Strbian (D)

From the Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, PA; Department of Neurology (A.H.K.), University of Ioannina School of Medicine, Greece; Department of Neurology (N.G., A.W.A., A.V.A, G.T.), University of Tennessee Health Science Center, Memphis; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (D.S.), Helsinki University Central Hospital, Finland; Second Department of Neurology (A.H.K., L.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; and Clinical Innovation and Research Institute (J.C.G.), Memorial Hermann Hospital-Texas Medical Center, Houston.

Lina Palaiodimou (L)

From the Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, PA; Department of Neurology (A.H.K.), University of Ioannina School of Medicine, Greece; Department of Neurology (N.G., A.W.A., A.V.A, G.T.), University of Tennessee Health Science Center, Memphis; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (D.S.), Helsinki University Central Hospital, Finland; Second Department of Neurology (A.H.K., L.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; and Clinical Innovation and Research Institute (J.C.G.), Memorial Hermann Hospital-Texas Medical Center, Houston.

Theodore Karapanayiotides (T)

From the Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, PA; Department of Neurology (A.H.K.), University of Ioannina School of Medicine, Greece; Department of Neurology (N.G., A.W.A., A.V.A, G.T.), University of Tennessee Health Science Center, Memphis; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (D.S.), Helsinki University Central Hospital, Finland; Second Department of Neurology (A.H.K., L.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; and Clinical Innovation and Research Institute (J.C.G.), Memorial Hermann Hospital-Texas Medical Center, Houston.

Anne W Alexandrov (AW)

From the Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, PA; Department of Neurology (A.H.K.), University of Ioannina School of Medicine, Greece; Department of Neurology (N.G., A.W.A., A.V.A, G.T.), University of Tennessee Health Science Center, Memphis; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (D.S.), Helsinki University Central Hospital, Finland; Second Department of Neurology (A.H.K., L.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; and Clinical Innovation and Research Institute (J.C.G.), Memorial Hermann Hospital-Texas Medical Center, Houston.

James C Grotta (JC)

From the Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, PA; Department of Neurology (A.H.K.), University of Ioannina School of Medicine, Greece; Department of Neurology (N.G., A.W.A., A.V.A, G.T.), University of Tennessee Health Science Center, Memphis; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (D.S.), Helsinki University Central Hospital, Finland; Second Department of Neurology (A.H.K., L.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; and Clinical Innovation and Research Institute (J.C.G.), Memorial Hermann Hospital-Texas Medical Center, Houston.

Andrei V Alexandrov (AV)

From the Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, PA; Department of Neurology (A.H.K.), University of Ioannina School of Medicine, Greece; Department of Neurology (N.G., A.W.A., A.V.A, G.T.), University of Tennessee Health Science Center, Memphis; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (D.S.), Helsinki University Central Hospital, Finland; Second Department of Neurology (A.H.K., L.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; and Clinical Innovation and Research Institute (J.C.G.), Memorial Hermann Hospital-Texas Medical Center, Houston.

Georgios Tsivgoulis (G)

From the Department of Neurology (K.M.), Allegheny Health Network, Pittsburgh, PA; Department of Neurology (A.H.K.), University of Ioannina School of Medicine, Greece; Department of Neurology (N.G., A.W.A., A.V.A, G.T.), University of Tennessee Health Science Center, Memphis; Department of Neurology (N.A.), Karolinska University Hospital; Department of Clinical Neuroscience (N.A.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (D.S.), Helsinki University Central Hospital, Finland; Second Department of Neurology (A.H.K., L.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotle University of Thessaloniki, Greece; and Clinical Innovation and Research Institute (J.C.G.), Memorial Hermann Hospital-Texas Medical Center, Houston. tsivgoulisgiorg@yahoo.gr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH